Webinar - The Rise of Biosimilars: How Payers Should Plan for 2023 and Beyond
Biosimilars are poised to disrupt the drug chain in 2023. What do brokers and plan sponsors need to know?
3 Patient Access Strategies Setting Innovative Brands Apart
The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?
7 Indicators that Your Drug is a Strong Candidate for Accumulator and Maximizer Programs
How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.
The Accumulator Adjustment Ruling of 2023 – What’s Next for Brands
On May 17, 2022, the U.S. District Court for DC ruled against the “accumulator adjustment rule.” What impact will this have on pharma?
3 Patient Access Strategies for New Biosimilar Brands
As biosimilars gain more popularity in the market, pharma manufacturers must think differently about launch strategies to gain market share.
What are Biosimilars and Why Do They Matter?
If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?
6 Takeaways from the Asembia 2022 Specialty Pharmacy Summit
6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?
What Pharma Should Know About How Employers are Approaching Accumulators and Maximizers
Truveris covers exactly how leading employer groups and their brokers are implementing copay maximizers and accumulators.
3 Ways to Avoid Drug Launch Mistakes
With so much importance placed on the launch of a new drug, how should pharma brands ensure a successful launch?
How are COVID-19 Variants Impacting Pharmaceutical Brands?
With Delta and Omicron, the COVID-19 pandemic carries on. How are these variants impacting pharma brands?
3 Strategies for Pharma Brands to Navigate the January Claims Drop
Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?
Asembia 2021: Four Key Takeaways
Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.
The 340B Program: How Manufacturers, Plan Sponsors, and Brokers Should React
340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?
The Impact of COVID-19 on Brand Prescribing and Claims
Read Truveris’ data report on the impact of COVID-19 on pharma, specifically prescribing and claims numbers for branded drugs.
5 Misconceptions about Loss of Exclusivity that Impact Patient Retention
Loss of exclusivity can feel like a dramatic shift, forever changing a drug’s profitability. However, this doesn’t have to be your brand’s fate.
Generic Drug Differences and MAC Pricing: What Plan Sponsors Need to Know
Generic versions of brand name medications are not all the same. Understanding their differences and their implications on MAC pricing is critical for choosing the most cost-effective PBM.
What's the Difference between a Specialty Drug and a Non-Specialty Drug?
Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.
Three Ways to Help Patients Navigate the Medicare Coverage Gap
Many Medicare patients end up not filling their high-cost prescriptions due to the Medicare coverage gap. What can manufacturers do to help Medicare patients stay adherent?
3 Ways to Build Better Copay Assistance Programs
Adopting these three approaches can help manufacturers to build a more effective affordability program.
Is Your Patient Abandonment Rate Really What You Think it is?
Your entire access strategy hinges on your patient abandonment rate. Is your patient abandonment rate calculated correctly?
Is Your Copay Program Costing You More Than It’s Earning? Keep These Top 5 Metrics In Mind
While the goals of every copay program vary, the top 5 essential ROI metrics to track its success stay the same.